Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 37

1.

Kinetic Modeling of the Tau PET Tracer 18F-AV-1451 in Human Healthy Volunteers and Alzheimer Disease Subjects.

Barret O, Alagille D, Sanabria S, Comley RA, Weimer RM, Borroni E, Mintun M, Seneca N, Papin C, Morley T, Marek K, Seibyl JP, Tamagnan GD, Jennings D.

J Nucl Med. 2017 Jul;58(7):1124-1131. doi: 10.2967/jnumed.116.182881. Epub 2016 Dec 1.

2.

Positron emission tomography measurement of brain MAO-B inhibition in patients with Alzheimer's disease and elderly controls after oral administration of sembragiline.

Sturm S, Forsberg A, Nave S, Stenkrona P, Seneca N, Varrone A, Comley RA, Fazio P, Jamois C, Nakao R, Ejduk Z, Al-Tawil N, Akenine U, Halldin C, Andreasen N, Ricci B.

Eur J Nucl Med Mol Imaging. 2017 Mar;44(3):382-391. doi: 10.1007/s00259-016-3510-6. Epub 2016 Sep 16.

3.

(11)C-PBR28 imaging in multiple sclerosis patients and healthy controls: test-retest reproducibility and focal visualization of active white matter areas.

Park E, Gallezot JD, Delgadillo A, Liu S, Planeta B, Lin SF, O'Connor KC, Lim K, Lee JY, Chastre A, Chen MK, Seneca N, Leppert D, Huang Y, Carson RE, Pelletier D.

Eur J Nucl Med Mol Imaging. 2015 Jun;42(7):1081-92. doi: 10.1007/s00259-015-3043-4. Epub 2015 Apr 2.

PMID:
25833352
4.

Anti-CD20 inhibits T cell-mediated pathology and microgliosis in the rat brain.

Anthony DC, Dickens AM, Seneca N, Couch Y, Campbell S, Checa B, Kersemans V, Warren EA, Tredwell M, Sibson NR, Gouverneur V, Leppert D.

Ann Clin Transl Neurol. 2014 Sep;1(9):659-69. doi: 10.1002/acn3.94. Epub 2014 Sep 16.

5.

Removal of a small C-terminal region of JCV and SV40 large T antigens has differential effects on transformation.

Seneca NTM, Sáenz Robles MT, Pipas JM.

Virology. 2014 Nov;468-470:47-56. doi: 10.1016/j.virol.2014.07.038. Epub 2014 Aug 16.

6.

Palladium mediated ¹¹C-cyanation and characterization in the non-human primate brain of the novel mGluR5 radioligand [¹¹C]AZD9272.

Andersson JD, Seneca N, Truong P, Wensbo D, Raboisson P, Farde L, Halldin C.

Nucl Med Biol. 2013 May;40(4):547-53. doi: 10.1016/j.nucmedbio.2012.12.012. Epub 2013 Mar 28.

PMID:
23541825
7.

Correlation of 18F-FDG PET/CT assessments with disease activity and markers of inflammation in patients with early rheumatoid arthritis following the initiation of combination therapy with triple oral antirheumatic drugs.

Roivainen A, Hautaniemi S, Möttönen T, Nuutila P, Oikonen V, Parkkola R, Pricop L, Ress R, Seneca N, Seppänen M, Yli-Kerttula T.

Eur J Nucl Med Mol Imaging. 2013 Feb;40(3):403-10. doi: 10.1007/s00259-012-2282-x. Epub 2012 Nov 15.

PMID:
23229747
8.

Occupancy of dopamine D₂ and D₃ and serotonin 5-HT₁A receptors by the novel antipsychotic drug candidate, cariprazine (RGH-188), in monkey brain measured using positron emission tomography.

Seneca N, Finnema SJ, Laszlovszky I, Kiss B, Horváth A, Pásztor G, Kapás M, Gyertyán I, Farkas S, Innis RB, Halldin C, Gulyás B.

Psychopharmacology (Berl). 2011 Dec;218(3):579-87. doi: 10.1007/s00213-011-2343-z. Epub 2011 May 28.

9.

Effects of ketoconazole on the biodistribution and metabolism of [11C]loperamide and [11C]N-desmethyl-loperamide in wild-type and P-gp knockout mice.

Seneca N, Zoghbi SS, Shetty HU, Tuan E, Kannan P, Taku A, Innis RB, Pike VW.

Nucl Med Biol. 2010 Apr;37(3):335-45. doi: 10.1016/j.nucmedbio.2009.12.010.

10.

Dopamine beta-hydroxylase-deficient mice have normal densities of D(2) dopamine receptors in the high-affinity state based on in vivo PET imaging and in vitro radioligand binding.

Skinbjerg M, Seneca N, Liow JS, Hong J, Weinshenker D, Pike VW, Halldin C, Sibley DR, Innis RB.

Synapse. 2010 Sep;64(9):699-703. doi: 10.1002/syn.20781.

11.

Biodistribution and dosimetry in humans of two inverse agonists to image cannabinoid CB1 receptors using positron emission tomography.

Terry GE, Hirvonen J, Liow JS, Seneca N, Tauscher JT, Schaus JM, Phebus L, Felder CC, Morse CL, Pike VW, Halldin C, Innis RB.

Eur J Nucl Med Mol Imaging. 2010 Aug;37(8):1499-506. doi: 10.1007/s00259-010-1411-7. Epub 2010 Mar 24.

12.

P-glycoprotein function at the blood-brain barrier in humans can be quantified with the substrate radiotracer 11C-N-desmethyl-loperamide.

Kreisl WC, Liow JS, Kimura N, Seneca N, Zoghbi SS, Morse CL, Herscovitch P, Pike VW, Innis RB.

J Nucl Med. 2010 Apr;51(4):559-66. doi: 10.2967/jnumed.109.070151. Epub 2010 Mar 17.

13.

D2 dopamine receptor internalization prolongs the decrease of radioligand binding after amphetamine: a PET study in a receptor internalization-deficient mouse model.

Skinbjerg M, Liow JS, Seneca N, Hong J, Lu S, Thorsell A, Heilig M, Pike VW, Halldin C, Sibley DR, Innis RB.

Neuroimage. 2010 May 1;50(4):1402-7. doi: 10.1016/j.neuroimage.2010.01.055. Epub 2010 Jan 22.

14.

Human brain imaging and radiation dosimetry of 11C-N-desmethyl-loperamide, a PET radiotracer to measure the function of P-glycoprotein.

Seneca N, Zoghbi SS, Liow JS, Kreisl W, Herscovitch P, Jenko K, Gladding RL, Taku A, Pike VW, Innis RB.

J Nucl Med. 2009 May;50(5):807-13. doi: 10.2967/jnumed.108.058453. Epub 2009 Apr 16.

15.

Neuroimaging and physiological evidence for involvement of glutamatergic transmission in regulation of the striatal dopaminergic system.

Tokunaga M, Seneca N, Shin RM, Maeda J, Obayashi S, Okauchi T, Nagai Y, Zhang MR, Nakao R, Ito H, Innis RB, Halldin C, Suzuki K, Higuchi M, Suhara T.

J Neurosci. 2009 Feb 11;29(6):1887-96. doi: 10.1523/JNEUROSCI.2559-08.2009.

16.

P-glycoprotein function at the blood-brain barrier imaged using 11C-N-desmethyl-loperamide in monkeys.

Liow JS, Kreisl W, Zoghbi SS, Lazarova N, Seneca N, Gladding RL, Taku A, Herscovitch P, Pike VW, Innis RB.

J Nucl Med. 2009 Jan;50(1):108-15. doi: 10.2967/jnumed.108.056226. Epub 2008 Dec 17.

17.

Synthesis and evaluation of [N-methyl-11C]N-desmethyl-loperamide as a new and improved PET radiotracer for imaging P-gp function.

Lazarova N, Zoghbi SS, Hong J, Seneca N, Tuan E, Gladding RL, Liow JS, Taku A, Innis RB, Pike VW.

J Med Chem. 2008 Oct 9;51(19):6034-43. doi: 10.1021/jm800510m. Epub 2008 Sep 11.

18.

Occupancy of dopamine D2/3 receptors in rat brain by endogenous dopamine measured with the agonist positron emission tomography radioligand [11C]MNPA.

Seneca N, Zoghbi SS, Skinbjerg M, Liow JS, Hong J, Sibley DR, Pike VW, Halldin C, Innis RB.

Synapse. 2008 Oct;62(10):756-63. doi: 10.1002/syn.20549.

19.

Kinetic brain analysis and whole-body imaging in monkey of [11C]MNPA: a dopamine agonist radioligand.

Seneca N, Skinbjerg M, Zoghbi SS, Liow JS, Gladding RL, Hong J, Kannan P, Tuan E, Sibley DR, Halldin C, Pike VW, Innis RB.

Synapse. 2008 Sep;62(9):700-9. doi: 10.1002/syn.20544.

20.

[11C]AZ10419369: a selective 5-HT1B receptor radioligand suitable for positron emission tomography (PET). Characterization in the primate brain.

Pierson ME, Andersson J, Nyberg S, McCarthy DJ, Finnema SJ, Varnäs K, Takano A, Karlsson P, Gulyás B, Medd AM, Lee CM, Powell ME, Heys JR, Potts W, Seneca N, Mrzljak L, Farde L, Halldin C.

Neuroimage. 2008 Jul 1;41(3):1075-85. doi: 10.1016/j.neuroimage.2008.02.063. Epub 2008 Mar 14.

PMID:
18434202
21.

Synthesis and evaluation of N-methyl and S-methyl 11C-labeled 6-methylthio-2-(4'-N,N-dimethylamino)phenylimidazo[1,2-a]pyridines as radioligands for imaging beta-amyloid plaques in Alzheimer's disease.

Cai L, Liow JS, Zoghbi SS, Cuevas J, Baetas C, Hong J, Shetty HU, Seneca NM, Brown AK, Gladding R, Temme SS, Herman MM, Innis RB, Pike VW.

J Med Chem. 2008 Jan 10;51(1):148-58. Epub 2007 Dec 14.

PMID:
18078311
22.

Brain and whole-body imaging in nonhuman primates with [11C]MeS-IMPY, a candidate radioligand for beta-amyloid plaques.

Seneca N, Cai L, Liow JS, Zoghbi SS, Gladding RL, Hong J, Pike VW, Innis RB.

Nucl Med Biol. 2007 Aug;34(6):681-9.

PMID:
17707808
23.

Atomoxetine occupies the norepinephrine transporter in a dose-dependent fashion: a PET study in nonhuman primate brain using (S,S)-[18F]FMeNER-D2.

Seneca N, Gulyás B, Varrone A, Schou M, Airaksinen A, Tauscher J, Vandenhende F, Kielbasa W, Farde L, Innis RB, Halldin C.

Psychopharmacology (Berl). 2006 Sep;188(1):119-27. Epub 2006 Aug 4.

PMID:
16896954
24.

Development of new brain imaging agents based upon nocaine-modafinil hybrid monoamine transporter inhibitors.

Musachio JL, Hong J, Ichise M, Seneca N, Brown AK, Liow JS, Halldin C, Innis RB, Pike VW, He R, Zhou J, Kozikowski AP.

Bioorg Med Chem Lett. 2006 Jun 15;16(12):3101-4. Epub 2006 Apr 18.

PMID:
16621532
25.

Effect of amphetamine on dopamine D2 receptor binding in nonhuman primate brain: a comparison of the agonist radioligand [11C]MNPA and antagonist [11C]raclopride.

Seneca N, Finnema SJ, Farde L, Gulyás B, Wikström HV, Halldin C, Innis RB.

Synapse. 2006 Apr;59(5):260-9.

PMID:
16416444
26.

Whole-body biodistribution, radiation dosimetry estimates for the PET norepinephrine transporter probe (S,S)-[18F]FMeNER-D2 in non-human primates.

Seneca N, Andree B, Sjoholm N, Schou M, Pauli S, Mozley PD, Stubbs JB, Liow JS, Sovago J, Gulyás B, Innis R, Halldin C.

Nucl Med Commun. 2005 Aug;26(8):695-700.

PMID:
16000987
27.

Quantification of brain phosphodiesterase 4 in rat with (R)-[11C]Rolipram-PET.

Fujita M, Zoghbi SS, Crescenzo MS, Hong J, Musachio JL, Lu JQ, Liow JS, Seneca N, Tipre DN, Cropley VL, Imaizumi M, Gee AD, Seidel J, Green MV, Pike VW, Innis RB.

Neuroimage. 2005 Jul 15;26(4):1201-10.

PMID:
15961054
28.

A preliminary PET evaluation of the new dopamine D2 receptor agonist [11C]MNPA in cynomolgus monkey.

Finnema SJ, Seneca N, Farde L, Shchukin E, Sóvágó J, Gulyás B, Wikström HV, Innis RB, Neumeyer JL, Halldin C.

Nucl Med Biol. 2005 May;32(4):353-60.

PMID:
15878504
29.

Preparation of highly specific radioactivity [18F]flumazenil and its evaluation in cynomolgus monkey by positron emission tomography.

Ryzhikov NN, Seneca N, Krasikova RN, Gomzina NA, Shchukin E, Fedorova OS, Vassiliev DA, Gulyás B, Hall H, Savic I, Halldin C.

Nucl Med Biol. 2005 Feb;32(2):109-16.

PMID:
15721755
30.

Whole-body biodistribution and radiation dosimetry estimates for the PET dopamine transporter probe 18F-FECNT in non-human primates.

Tipre DN, Fujita M, Chin FT, Seneca N, Vines D, Liow JS, Pike VW, Innis RB.

Nucl Med Commun. 2004 Jul;25(7):737-42.

31.

Evaluation of anesthesia effects on [18F]FDG uptake in mouse brain and heart using small animal PET.

Toyama H, Ichise M, Liow JS, Vines DC, Seneca NM, Modell KJ, Seidel J, Green MV, Innis RB.

Nucl Med Biol. 2004 Feb;31(2):251-6.

PMID:
15013491
32.

Effect of scatter correction on the compartmental measurement of striatal and extrastriatal dopamine D2 receptors using [123I]epidepride SPET.

Fujita M, Varrone A, Kim KM, Watabe H, Zoghbi SS, Seneca N, Tipre D, Seibyl JP, Innis RB, Iida H.

Eur J Nucl Med Mol Imaging. 2004 May;31(5):644-54. Epub 2004 Jan 17.

PMID:
14730406
33.
34.

Cerebral benzodiazepine receptors in depressed patients measured with [123I]iomazenil SPECT.

Kugaya A, Sanacora G, Verhoeff NP, Fujita M, Mason GF, Seneca NM, Bozkurt A, Khan SA, Anand A, Degen K, Charney DS, Zoghbi SS, Baldwin RM, Seibyl JP, Innis RB.

Biol Psychiatry. 2003 Oct 15;54(8):792-9.

PMID:
14550678
35.

Quantification of nicotinic acetylcholine receptors in human brain using [123I]5-I-A-85380 SPET.

Fujita M, Ichise M, van Dyck CH, Zoghbi SS, Tamagnan G, Mukhin AG, Bozkurt A, Seneca N, Tipre D, DeNucci CC, Iida H, Vaupel DB, Horti AG, Koren AO, Kimes AS, London ED, Seibyl JP, Baldwin RM, Innis RB.

Eur J Nucl Med Mol Imaging. 2003 Dec;30(12):1620-9. Epub 2003 Oct 2.

PMID:
14523584
36.

Changes in human in vivo serotonin and dopamine transporter availabilities during chronic antidepressant administration.

Kugaya A, Seneca NM, Snyder PJ, Williams SA, Malison RT, Baldwin RM, Seibyl JP, Innis RB.

Neuropsychopharmacology. 2003 Feb;28(2):413-20. Epub 2002 Jul 19.

37.

Brain SPECT imaging of amphetamine-induced dopamine release in euthymic bipolar disorder patients.

Anand A, Verhoeff P, Seneca N, Zoghbi SS, Seibyl JP, Charney DS, Innis RB.

Am J Psychiatry. 2000 Jul;157(7):1108-14.

PMID:
10873919

Supplemental Content

Loading ...
Support Center